Put your CT Throughput in the Fast Lane

INTRODUCING CT ExprèS

The individuals who appear are for illustrative purposes only. All persons depicted are models and not real patients.

Committed to Science, Committed to You.
CT IS FACING MULTIPLE CHALLENGES
Increasing patient numbers and declining revenues will require a new solution

Rising Medicare enrollment is anticipated to compound demand

<table>
<thead>
<tr>
<th>Year</th>
<th>Historical</th>
<th>Projected</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>37.6</td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td>38.7</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>42.6</td>
<td></td>
</tr>
<tr>
<td>2010</td>
<td>47.7</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>55.6</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>64.3</td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td>73.5</td>
<td></td>
</tr>
<tr>
<td>2030</td>
<td>81.5</td>
<td></td>
</tr>
<tr>
<td>2035</td>
<td>86.5</td>
<td></td>
</tr>
</tbody>
</table>

Historical Projected

Annual payment cuts anticipated to steadily decrease revenue

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>($)</td>
<td>($4B)</td>
<td>($14B)</td>
<td>($21B)</td>
<td>($25B)</td>
<td>($32B)</td>
<td>($42B)</td>
<td>($53B)</td>
<td>($64B)</td>
<td>($75B)</td>
<td>($86B)</td>
</tr>
</tbody>
</table>

Affordable Care Act Medicare reform directly cuts fees-for-service, reducing payments.

Technologists are challenged to meet current demands

Each scan requires: 34 tasks

Average procedure time: 27 minutes

Is your CT suite feeling the pressure?

The individuals who appear are for illustrative purposes only. All persons depicted are models and not real patients.
PUT YOUR CT SUITE IN THE CT Exprès LANE
Introducing the first syringe-less power injector for CT in the U.S.

In a prospective study of 275 consecutive outpatients, utility of CT Exprès was compared with a dual-syringe system. The comparison was carried out in a single center utilizing 2 scanner rooms, which shared a common console room.

65% less preparation time
Average preparation time:
- Syringe-based injector: 139 seconds
- CT Exprès: 48 seconds (P<.001)

75% less releasing time
Average releasing time:
- Syringe-based injector: 32 seconds
- CT Exprès: 8 seconds (P<.001)

CT Exprès saved over 2 minutes/exam and increased throughput by 2.6 patients/day

What would 2 additional scans per day mean to you?

"We were scanning 35-40 patients per day and now that’s up to 45-50. That’s quite an increase in efficiency."
— Head of Radiology, Geneva University Hospital

Contrast Media Waste Eliminated
Average contrast waste per exam:
- Syringe-based injector: 11 mL
- CT Exprès: 0 mL (P<.001)

When studied across 135 patients, CT Exprès saved approximately 1500 mL of contrast

More throughput, less waste

"We switched from another injector for the ease of use. Less mess. Less work. It’s quite easy and you don’t lose contrast between patients."
— Head of Radiology, Geneva University Hospital

The individuals who appear are for illustrative purposes only. All persons depicted are models and not real patients.
YOUR PATH TO AN ENTIRELY NEW EXPERIENCE
Empowering the efficiency, productivity, and satisfaction of your staff

CT Exprès demonstrated:

Higher performance rating
Syringe-based injector

<table>
<thead>
<tr>
<th>CT Exprès</th>
<th>Syringe-based injector</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.3 (P=.006)</td>
<td>6.3</td>
</tr>
</tbody>
</table>

Higher ease of patient preparation rating
Syringe-based injector

<table>
<thead>
<tr>
<th>CT Exprès</th>
<th>Syringe-based injector</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.8 (P=8.04 x 10^-7)</td>
<td>4.5</td>
</tr>
</tbody>
</table>

Higher user-friendliness rating
Syringe-based injector

<table>
<thead>
<tr>
<th>CT Exprès</th>
<th>Syringe-based injector</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.2 (P=.011)</td>
<td>6.3</td>
</tr>
</tbody>
</table>

Equivalent image quality
Syringe-based injector

<table>
<thead>
<tr>
<th>CT Exprès</th>
<th>Syringe-based injector</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5 (P=.701)</td>
<td>4.5</td>
</tr>
</tbody>
</table>

Get to know the future

Built to streamline workflow
- No syringes for reduced filling and cleanup
- User-friendly interface with dual touch screens
- Easily switch between contrast bottles at any point during the procedure
- Able to program/store protocols with up to 8 phases

Built to maximize safety
- Closed system minimizes the risk for air embolism and contaminants
- Designed to minimize risk of contamination
- The only system with 4 air detection sensors for increased patient safety

Built for today’s clinical environment

Technologists notice a significant difference and so will you.
IMPORTANT SAFETY INFORMATION

CT Exprès Contrast Media Delivery System

INDICATIONS

The CT Exprès Contrast Media Delivery System is indicated for controlled automatic administration, on the venous side, of contrast media and saline, to human subjects while undergoing examination by means of a computed tomography (CT) scanner.

The CT Exprès Contrast Media Delivery System is specifically indicated for use in CT procedures for the delivery of iopamidol contrast media as supplied in an Imaging Bulk Package (IBP), for a maximum of 20 bottles of contrast media or a maximum of ten (10) hours, whichever comes first, per Day Set [HP]. The Bottle Spike disposable is for single-bottle use only and must be discarded with the contrast media bottle. The Patient Set must be discarded after each patient procedure.

CONTRAINDICATIONS

This device is not intended for injection of contrast media for coronary arteriography, or for any other use for which the device is not indicated.

ISOVUE® and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc. CT Exprès is a trademark of Bracco Ingegneria S.A.

Orders are acceptable for ISOVUE-300 or ISOVUE-370. Please download full Prescribing Information for ISOVUE IBP by clicking here.

ORDERING INFORMATION

<table>
<thead>
<tr>
<th>Code</th>
<th>ISOVUE®-300* (iopamidol injection 61%)</th>
<th>ISOVUE-370* (iopamidol injection 76%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>131545</td>
<td>Ten 200 mL bottles¹</td>
<td>Ten 200 mL bottles¹</td>
</tr>
<tr>
<td>131595</td>
<td>Six 500 mL bottles¹</td>
<td>Six 500 mL bottles¹</td>
</tr>
<tr>
<td>0270-1315-45</td>
<td></td>
<td>0270-1316-45</td>
</tr>
</tbody>
</table>

*Concentration (mgI/mL), Imaging Bulk Package.

References


IMPORTANT SAFETY INFORMATION

ISOVUE®-300 or ISOVUE-370 Imaging Bulk Package

INDICATIONS AND USAGE FOR ISOVUE IN CT PROCEDURES (IMAGING BULK PACKAGE):

ISOVUE®-300, 370 IMAGING BULK PACKAGE

ISOVUE (iopamidol injection) Imaging Bulk Package (IBP) is indicated for intravenous contrast enhancement of computed tomographic (CT) imaging of the head and body in adult and pediatric patients.

IMPORTANT SAFETY INFORMATION

ISOVUE IS NOT FOR INTRATHECAL USE. Iopamidol injection is available as Isovue-M® for intrathecal administration.

Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger and repeat doses are administered. Radiopaque contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemias, particularly in those with therapeutically resistant anuria. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure. Diabetic nephropathy may predispose to acute renal failure following intravascular contrast media administration. Acute renal failure following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides. Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). Patients should be well hydrated prior to and following iopamidol administration. The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies). Please download full Prescribing Information for ISOVUE IBP by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CT Exprès™

For use with ISOVUE® (iopamidol injection) Imaging Bulk Package

Only CT Exprès places your suite in the fast lane

References